Menu Search
Equities

Medtronic PLC

2M6:DUS

Medtronic PLC

Actions
  • Price (EUR)77.04
  • Today's Change1.16 / 1.53%
  • Shares traded0.00
  • 1 Year change-16.70%
  • Beta--
Data delayed at least 15 minutes, as of May 30 2023 16:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Medtronic plc is a global healthcare technology company. The Company develops, manufactures, and markets its medical devices and technologies to hospitals, physicians, clinicians, and patients. Its operating segments include Cardiovascular, Medical Surgical, Neuroscience and Diabetes. Cardiovascular products include pacemakers, insertable cardiac monitors, and cardiac resynchronization therapy devices. Medical Surgical products include patient care from diagnosis to recovery, with a focus on diseases of the gastrointestinal tract, lungs, pelvic region, kidneys, obesity, and preventable complications. Neuroscience products include various spinal implants, bone graft substitutes, biologic products, image-guided surgery and intra-operative imaging systems. Diabetes products include insulin pumps, continuous glucose monitoring (CGM) systems, consumables, and smart insulin pen systems. It also provides PROPEL and SINUVA. The Company is focused on cardiac ablation portfolio.

  • Revenue in USD (TTM)30.77bn
  • Net income in USD4.06bn
  • Incorporated2014
  • Employees95.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		MDT:NYQ since
announced		Transaction
value
Cathworks LtdAnnounced12 Jul 202212 Jul 2022Announced-6.98%--
Data delayed at least 15 minutes, as of May 30 2023 16:45 BST.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.